Senti Biosciences (SNTI) Stock Price, News & Analysis

Company Overview

Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue.

Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs. Its pipeline has included logic-gated therapies designed to integrate multiple antigen signals, with investigational programs targeting cancers such as acute myeloid leukemia and colorectal cancer. These products remain subject to clinical development and regulatory review.

Founded in 2016, the company is headquartered in South San Francisco, California, and primarily conducts its research and development activities in the United States. Senti Biosciences was founded by scientists and entrepreneurs in the fields of synthetic biology and cell therapy, including Dr. Tim Lu, who has served as a senior company leader and co-founder.

Key Stats

• Today's Range: $0.14 to $0.16
• 50-Day Range: $0.14 to $0.35
• 52-Week Range: $0.14 to $2.88
• Volume: 31,254 shs
• Average Volume: 1.19 million shs
• Market Capitalization: $4.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

Senti Biosciences Stock Analysis - MarketRank™

Senti Biosciences scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Senti Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Senti Biosciences has a consensus price target of $9.00, representing about 6,150.0% upside from its current price of $0.14.

Amount of Analyst Coverage

Senti Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Senti Biosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senti Biosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senti Biosciences has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.70% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently increased by 160.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senti Biosciences does not currently pay a dividend.

Dividend Growth

Senti Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.41

News Sentiment

Senti Biosciences has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 1 article on an average week.

Search Interest

4 people have searched for SNTI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.12% of the stock of Senti Biosciences is held by insiders.

Percentage Held by Institutions

25.70% of the stock of Senti Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNTI
• CIK: 1854270
• Web: www.sentibio.com
• Phone: 650-239-2030
• Fax: N/A
• Employees: 39
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Senti Biosciences: $9.00
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +6,106.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.44 million
• Net Margins: N/A
• Pretax Margin: -90,116.36%
• Return on Equity: -1,629.80%
• Return on Assets: -119.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.83
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 225.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 31,150,000
• Free Float: 30,173,000
• Market Cap: $4.52 million
• Optionable: Not Optionable
• Beta: 2.31